This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Design System, The Toro Company, Charles River Laboratories International and ICON
by Zacks Equity Research
Zacks.com featured highlights include: Design System, The Toro Company, Charles River Laboratories International and ICON
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Icon PLC (ICLR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River Laboratories (CRL) Q3 Earnings Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 3.05% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More
by Zacks Equity Research
Rise in senior population, shift of care to lower-cost settings and decline in unemployment are likely to have driven healthcare sector earnings.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Names Two Leaders for Major Business Wings
by Zacks Equity Research
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
What Makes Charles River (CRL) a New Buy Stock
by Zacks Equity Research
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charles River Laboratories (CRL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 5.16% and -0.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More
by Zacks Equity Research
Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.
Earnings Preview: Charles River Laboratories (CRL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc's Partnership to Form Pediatric Telehealth Platform
by Zacks Equity Research
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.
Top Ranked Growth Stocks to Buy for April 12th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 12th.
Charles River Laboratories (CRL) Is Up 2.99% in One Week: What You Should Know
by Zacks Equity Research
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
by Zacks Equity Research
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Charles River (CRL) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Growth Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 2nd
Encouraging Near-Term Outlook for Medical Services Industry
by Urmimala Biswas
With growing importance of effective healthcare management, the medical service industry is becoming an integral part of the modern healthcare mechanism.
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo